Cationic cell-penetrating peptides are potent furin inhibitors

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Ramos Molina, Bruno ^a   Lick, Adam N ^a   Shirazi, Amir Nasrolahi ^b   Oh, Donghoon ^b   Tiwari, Rakesh ^b   El Sayed, Naglaa Salem ^b   Parang, Keykavous ^b   Lindberg, Iris ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CHAPMAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PENETRATING PEPTIDE; CYCLIC POLYARGININE PEPTIDE; FURIN; POLYARGININE; SERINE PROTEINASE; TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN [47-54]; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; MERCAPTAMINE; PEP-1 PEPTIDE; PEPTIDE; PEPTIDE FRAGMENT; TAT PEPTIDE (47-57), HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CELL CULTURE; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FIBROSARCOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR TRANSPORT; MOLECULAR RECOGNITION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL MOTION; CHEMISTRY; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; TUMOR CELL LINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIMICROBIAL CATIONIC PEPTIDES; CELL LINE, TUMOR; CELL MOVEMENT; CELL-PENETRATING PEPTIDES; CYSTEAMINE; FURIN; HIV-1; HUMANS; PEPTIDE FRAGMENTS; PEPTIDES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84938283574     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130417     Document Type: Article

References (51)

1. Joliot A, Prochiantz A (2004) Transduction peptides: from technology to physiology. Nat Cell Biol 6: 189-196. PMID: 15039791
2. Verdurmen WP, Brock R (2011) Biological responses towards cationic peptides and drug carriers. Trends Pharmacol Sci 32: 116-124. doi: 10.1016/j.tips.2010.11.005 PMID: 21167610
3. Wadia JS, Dowdy SF (2005) Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 57: 579-596. PMID: 15722165
4. Wadia JS, Dowdy SF (2003) Modulation of cellular function by TAT mediated transduction of full length proteins. Curr Protein Pept Sci 4: 97-104. PMID: 12678849
5. Vivès E, Brodin P, Lebleu B (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272: 16010-16017. PMID: 9188504
6. Rudolph C, Plank C, Lausier J, Schillinger U, Müller RH, et al. (2003) Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem 278: 11411-11418. PMID: 12519756
7. Derossi D, Joliot AH, Chassaing G, Prochiantz A (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269: 10444-10450. PMID: 8144628
8. Gros E, Deshayes S, Morris MC, Aldrian-Herrada G, Depollier J, et al. (2006) A non-covalent peptidebased strategy for protein and peptide nucleic acid transduction. Biochim Biophys Acta 1758: 384-393. PMID: 16545342
9. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, et al. (2001) Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276: 5836-5840. PMID: 11084031
10. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, et al. (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A 97: 13003-13008. PMID: 11087855
11. Moutal A, Francois-Moutal L, Brittain JM, Khanna M, Khanna R (2014) Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphipathic cell penetrating peptides. Front Cell Neurosci 8: 471. doi: 10.3389/fncel.2014.00471 PMID: 25674050
12. Nasrolahi Shirazi A, Mandal D, Tiwari RK, Guo L, Lu W, et al. (2013) Cyclic peptide-capped gold nanoparticles as drug delivery systems. Mol Pharm 10: 500-511. doi: 10.1021/mp300448k PMID: 22998473
13. Oh D, Nasrolahi Shirazi A, Northup K, Sullivan B, Tiwari RK, et al. (2014) Enhanced cellular uptake of short polyarginine peptides through fatty acylation and cyclization. Mol Pharm 11: 2845-2854. doi: 10.1021/mp500203e PMID: 24978295
14. Nasrolahi Shirazi A, Tiwari RK, Oh D, Banerjee A, Yadav A, et al. (2013) Efficient delivery of cell impermeable phosphopeptides by a cyclic peptide amphiphile containing tryptophan and arginine. Mol Pharm 10: 2008-2020. doi: 10.1021/mp400046u PMID: 23537165
15. Kacprzak MM, Peinado JR, Than ME, Appel J, Henrich S, et al. (2004) Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-D-arginine. J Biol Chem 279: 36788-36794. PMID: 15197180
16. Fugere M, Appel J, Houghten RA, Lindberg I, Day R (2007) Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: Use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences. Mol Pharmacol 71: 323-332. PMID: 17012622
17. Sarac MS, Cameron A, Lindberg I (2002) The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect Immun 70: 7136-7139. PMID: 12438396
18. Sarac MS, Peinado JR, Leppla SH, Lindberg I (2004) Protection against anthrax toxemia by hexa-Darginine in vitro and in vivo. Infect Immun 72: 602-605. PMID: 14688144
19. Peinado JR, Kacprzak MM, Leppla SH, Lindberg I (2004) Cross-inhibition between furin and lethal factor inhibitors. Biochem Biophys Res Commun 321: 601-605. PMID: 15358148
20. Gagnon H, Beauchemin S, Kwiatkowska A, Couture F, D'Anjou F, et al. (2014) Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin. J Med Chem 57: 29-41. doi: 10.1021/jm400633d PMID: 24359257
21. Becker GL, Lu Y, Hardes K, Strehlow B, Levesque C, et al. (2012) Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem 287: 21992-22003. doi: 10.1074/jbc.M111.332643 PMID: 22539349
22. Nasrolahi Shirazi A, Tiwari R, Chhikara BS, Mandal D, Parang K (2013) Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs. Mol Pharm 10: 488-499. doi: 10.1021/mp3004034 PMID: 23301519
23. Vivoli M, Caulfield TR, Martinez-Mayorga K, Johnson AT, Jiao GS, et al. (2012) Inhibition of prohormone convertases PC1/3 and PC2 by 2,5-dideoxystreptamine derivatives. Mol Pharmacol 81: 440-454. doi: 10.1124/mol.111.077040 PMID: 22169851
24. Coppola JM, Hamilton CA, Bhojani MS, Larsen MJ, Ross BD, et al. (2007) Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity. Anal Biochem 364: 19-29. PMID: 17316541
25. Coppola JM, Bhojani MS, Ross BD, Rehemtulla A (2008) A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia 10: 363-370. PMID: 18392131
26. Levesque C, Fugere M, Kwiatkowska A, Couture F, Desjardins R, et al. (2012) The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells. J Med Chem 55: 10501-10511. doi: 10.1021/jm3011178 PMID: 23126600
27. Longuespee R, Couture F, Levesque C, Kwiatkowska A, Desjardins R, et al. (2014) Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. Transl Oncol.
28. Cameron A, Appel J, Houghten RA, Lindberg I (2000) Polyarginines are potent furin inhibitors. J Biol Chem 275: 36741-36749. PMID: 10958789
29. Foerg C, Merkle HP (2008) On the biomedical promise of cell penetrating peptides: limits versus prospects. J Pharm Sci 97: 144-162. PMID: 17763452
30. Green M, Loewenstein PM (1988) Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55: 1179-1188. PMID: 2849509
31. Frankel AD, Pabo CO (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55: 1189-1193. PMID: 2849510
32. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572. PMID: 10477521
33. Liu BR, Lin MD, Chiang HJ, Lee HJ (2012) Arginine-rich cell-penetrating peptides deliver gene into living human cells. Gene 505: 37-45. doi: 10.1016/j.gene.2012.05.053 PMID: 22669044
34. Tung CH, Weissleder R (2003) Arginine containing peptides as delivery vectors. Adv Drug Deliv Rev 55: 281-294. PMID: 12564981
35. Bolhassani A (2011) Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta 1816: 232-246. doi: 10.1016/j.bbcan.2011.07.006 PMID: 21840374
36. Futaki S, Ohashi W, Suzuki T, Niwa M, Tanaka S, et al. (2001) Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem 12: 1005-1011. PMID: 11716693
37. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, et al. (2000) Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 6: 1253-1257. PMID: 11062537
38. Mitchell D, Kim D, Steinman L, Fathman C, Rothbard J (2000) Polyarginine enters cells more efficiently than other polycationic homopolymers. J Peptide Res 56: 318-325.
39. Shiryaev SA, Ratnikov BI, Chekanov AV, Sikora S, Rozanov DV, et al. (2006) Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem J 393: 503-511. PMID: 16229682
40. Remacle AG, Gawlik K, Golubkov VS, Cadwell GW, Liddington RC, et al. (2010) Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. Int J Biochem Cell Biol 42: 987-995. doi: 10.1016/j.biocel.2010.02.013 PMID: 20197107
41. Shiryaev SA, Remacle AG, Ratnikov BI, Nelson NA, Savinov AY, et al. (2007) Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem 282: 20847-20853. PMID: 17537721
42. Bassi DE, Mahloogi H, Klein-Szanto AJ (2000) The proprotein convertases furin and PACE4 play a significant role in tumor progression. Mol Carcinog 28: 63-69. PMID: 10900462
43. Sato H, Kinoshita TT, T., Nakayama K, Seiki M (1996) Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 393: 101-104. PMID: 8804434
44. Khatib AM, Siegfried G, Prat A, Luis J, Chrétien M, et al. (2001) Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J Biol Chem 27: 30686-30693.
45. Khatib AM, Siegfried G, Chretien M, Metrakos P, Seidah NG (2002) Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 160: 1921-1935. PMID: 12057895
46. Shirazi AN, Paquin KL, Howlett NG, Mandal D, Parang K (2014) Cyclic peptide-capped gold nanoparticles for enhanced siRNA delivery. Molecules 19: 13319-13331. doi: 10.3390/molecules190913319 PMID: 25170952
47. Nasrolahi Shirazi A, Tiwari RK, Oh D, Sullivan B, Kumar A, et al. (2014) Cyclic peptide-selenium nanoparticles as drug transporters. Mol Pharm 11: 3631-3641. doi: 10.1021/mp500364a PMID: 25184366
48. Qian Z, Liu T, Liu YY, Briesewitz R, Barrios AM, et al. (2013) Efficient delivery of cyclic peptides into mammalian cells with short sequence motifs. ACS Chem Biol 8: 423-431. doi: 10.1021/cb3005275 PMID: 23130658
49. Oh D, Sun J, Nasrolahi Shirazi A, LaPlante KL, Rowley DC, et al. (2014) Antibacterial activities of amphiphilic cyclic cell-penetrating peptides against multidrug-resistant pathogens. Mol Pharm 11: 3528-3536. doi: 10.1021/mp5003027 PMID: 25157458
50. Mandal D, Nasrolahi Shirazi A, Parang K (2011) Cell-penetrating homochiral cyclic peptides as nuclear-targeting molecular transporters. Angew Chem Int Ed Engl 50: 9633-9637. doi: 10.1002/anie.201102572 PMID: 21919161
51. Shen Y, Yu W, Hay JG, Sauthoff H (2011) Expressed cell-penetrating peptides can induce a bystander effect, but passage through the secretory pathway reduces protein transduction activity. Mol Ther 19: 903-912. doi: 10.1038/mt.2010.283 PMID: 21179011